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ABSTRACT 
 
Tyrosine kinases have been implicated in promoting tumorigenesis of several human cancers. 
Exploiting these vulnerabilities has been shown to be an effective anti-tumor strategy as demonstrated 
for example by the Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, for treatment of various blood 
cancers. Here, we characterize a new multiple kinase inhibitor, ARQ531, and evaluate its mechanism 
of action in preclinical models of acute myeloid leukemia. Treatment with ARQ531, by producing 
global signaling pathway deregulation, resulted in impaired cell cycle progression and survival in a 
large panel of leukemia cell lines and patient-derived tumor cells, regardless of the specific genetic 
background and/or the presence of bone marrow stromal cells. RNA-seq analysis revealed that 
ARQ531 constrained tumor cell proliferation and survival through Bruton’s tyrosine kinase and 
transcriptional program dysregulation, with proteasome-mediated MYB degradation and depletion of 
short-lived proteins that are crucial for tumor growth and survival, including ERK, MYC and MCL1. 
Finally, ARQ531 treatment was effective in a patient-derived leukemia mouse model with significant 
impairment of tumor progression and survival, at tolerated doses. These data justify the clinical 
development of ARQ531 as a promising targeted agent for the treatment of patients with acute myeloid 
leukemia. 
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INTRODUCTION 
Acute myeloid leukemia (AML) is an aggressive disease characterized by uncontrolled clonal 
proliferation of abnormal myeloid progenitor cells in the bone marrow and blood. Despite recent 
advances in its treatment, as many as 70% of patients aged 65 or older will die within 1 year of 
diagnosis. Efficacy of standard high-dose chemotherapy and stem cell transplantation is limited by 
treatment-related morbidity and mortality, especially in elderly patients. (1-3) Cancer treatment is 
undergoing a significant revolution from “one-size-fits-all” cytotoxic therapies to tailored approaches 
that precisely target molecular alterations. Notably, precision medicine, by linking specific genetic 
anomalies of tumors with available targeted therapies, is emerging as an innovative approach for AML 
treatment, with development of breakthrough drugs targeting specific molecular features (e.g. FLT3 
and IDH1/2 inhibitors). (4-6) However, identification of patients who will benefit from targeted 
therapies is more complex than simply identifying patients whose tumors harbor the targeted 
aberration. A rational combination of therapeutic agents may prevent the development of resistance to 
therapy, with molecular strategies aimed at targeting multiple pathways resulting in a more effective 
treatment across cancer subtypes.  
The Bruton’s tyrosine kinase (BTK), a member of the TEC family kinases, is a critical terminal kinase 
enzyme in the B-cell antigen receptor (BCR) signaling pathway. (7, 8) Its activation leads to BTK 
phosphorylation which in turn results in downstream events such as proliferation, immune function 
alteration and survival through multiple signaling cascades. (9) Chronic activation of BTK-mediated 
signaling represents a key driver for a number types of cancers, (10-14) including AML. (15-22) 
Therefore, new inhibitors are needed to better target tyrosine kinases in these patients. Recent studies 
have shown that oncogenic cellular dysregulation is critical for the activity of the anti-BTK targeting 
5 
 
agent ibrutinib, (23, 24) and that co-treatment with BET protein bromodomain antagonists or BCL-2 
inhibitors may enhance the efficacy of ibrutinib in tumor cells. (25, 26)   
Herein, we characterize ARQ531, a reversible small molecule inhibitor of BTK and several additional 
kinases, in preclinical models of AML. We provide evidence that ARQ531 greatly compromises 
survival of AML cells by inducing a “one shot” inhibition of multiple oncogenic transcriptional 
pathways. This results in potent anti-AML activity in a patient-derived xenograft (PDX) AML mice 
model, providing rationale for future clinical trials. 
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METHODS 
Reagents 
ARQ531 was provided by ArQule, Inc (Burlington, MA). The compound was dissolved in DMSO 
(Sigma, Aldrich) and stored at 10mM at -80°C for experiments. Ibrutinib (IBR), daunorubicin (DNR), 
cytarabine (ARA-C) and MG132 were purchased from Selleck Chemicals LLC (Houston, TX). ZVAD-
FMK was purchased from Promega (Cat.No G7232). 
Patient-derived xenograft AML cells 
Experiments were carried out on non-obese diabetic severe combined immunodeficient (NOD/SCID) 
interleukin-2 receptor g (IL-2Rg)–null (NSG) mice, 6 to 8-weeks-old. NSG mice were bred and housed 
under pathogen-free conditions in the animal facilities at the European Institute of Oncology–Italian 
Foundation for Cancer Research Institute of Molecular Oncology (IEO-IFOM, Milan, Italy). All animal 
experiments were carried out in strict accordance with the Italian laws (DLvo 26/2014 and following 
additions) and were approved by the institutional committee. NSG mice were engrafted with 300.000 
primary human AML cells (M4, acute myelomonocytic leukemia with FLT3wt). At day 19 post-graft, 
once a systemic xenograft was confirmed, mice were randomized into three groups: vehicle-treatment 
group (n=5), low-dose ARQ531 treatment group (25 mg/kg; n=5) and high-dose ARQ531 treatment 
group (37.5mg/kg; n = 5) and the percentage of human leukemic cells in peripheral blood was 
measured weekly till day 42. The phenotype of human cells in NSG mice was evaluated using the 
following anti-human antibodies: anti-CD117-PeCy7 (IMMU 103.44), -CD45-APC (J.33), -CD34-
APC-Cy7 (D3HL60.251) from Beckman-Coulter (Irving, TX, USA) and anti-mouse CD45-PE (30-
F11) from BD Biosciences to exclude murine cells contamination. Cell suspensions were evaluated by 
a 3-laser, 10-colour flow cytometer (Navios, Beckman Coulter, Brea, CA, USA) using analysis gates 
designed to exclude dead cells, platelets, and debris. Percentages of stained cells were determined and 
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compared to appropriate negative controls. Seven-aminoactinomycin D (7AAD) from Sigma-Aldrich 
was used to enumerate viable, apoptotic, and dead cells. 
Statistical analyses 
All in vitro experiments were repeated at least three times and performed in triplicate; a representative 
experiment is shown in each figure. All data are shown as mean ± standard deviation (SD). The 
Student's t test was used to compare two experimental groups using Graph-Pad Prism software 
(http://www.graphpad.com). The minimal level of significance was specified as p<0.05.  Survival 
analysis was performed by the Kaplan-Meier method, and the log-rank test was used to compare 
survival differences. Drug interaction were assessed by CalcuSyn 2 software (Biosoft), which is based 
on the Chou-Talalay method. Combination Index (CI) = 1, indicates additive effect; CI<1 indicates 
synergism; CI>1 indicates antagonism.  
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RESULTS 
ARQ 531 shows strong anti-AML activity but preserves normal hematopoietic stem cells (HSCs). 
In line with previously reported data, (15, 16) we observed that BTK is frequently dysregulated in 
AML, with mRNA levels significantly higher than in other cancer types. (Suppl. Fig. S1) To confirm 
its relative abundance, we screened a representative panel of human AML cell lines and primary blasts 
for BTK expression and activity by western blot. (Fig.1A) Protein was detectable in all AML-screened 
cells (15/15) and, more importantly, independent of specific mutational profiling. Similarly, BTK 
activity (measured by Y223 phosphorylation) was observed in FLT3 wild-type and FLT3 mutants as 
well. An analogous investigation was applied to a larger cohort of AML patients derived from The 
Cancer Genome Atlas (TCGA) database, which showed uniform expression of BTK transcript in 
different AML subtypes. Overall, these data, by confirming BTK presence in AML, support its 
targeting in this hematologic malignancy, as previously reported. (14, 15) 
ARQ531 is a recently described reversible BTK inhibitor with promising activity in mouse models of 
CLL and lymphomas. (27) Based on constitutively active BTK levels observed in AML cells, we 
evaluated the therapeutic activity of ARQ531 on these cells, using ibrutinib as a control. In-vitro 
efficacy screening was performed on cultured (n=8) and primary (n=13) AML cells, comparing the 
efficacy of both drugs. As shown in Figure 1B, ARQ531 exposure reduced in vitro viability more than 
ibrutinib (Fig.1C). IC50 analysis at 48 hours after treatment showed greater sensitivity to ARQ531 
compared with ibrutinib, which exhibited 10-fold lower activity. (Fig.1D) A significant anti-AML 
effect of ARQ531 was also observed on blasts from AML patients (n=13) regardless of mutational 
status, European leukemia Net (ELN) risk, and surface expression of CD117. (Fig.1E; Tab.1) 
Consistent with these data, a dose-dependent increase in the percentage of apoptotic and dead cells 
measured by Annexin V and Propidium iodide staining was also observed after ARQ531 treatment, 
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together with several apoptotic features including caspase 3 and poly (AD-ribose) polymerase cleavage 
as well as reduction of anti-apoptotic MCL-1 and BCL-2 protein expression. (Fig.1F-G and Suppl. 
Fig.S2A) Viability was completely restored by pan-caspase inhibitor Z-VAD pre-incubation (Suppl. 
Fig.S2B) In contrast, ibrutinib treatment resulted in weaker effects on apoptosis, thus suggesting that 
ARQ531 is more effective than ibrutinib probably because it induces downregulation of additional 
survival mechanisms.  
It is well known that the bone marrow microenvironment has a role in the promotion of tumor growth, 
survival and drug-resistance. (28) Therefore we treated AML cells in the presence of normal or 
leukemic mesenchymal stromal cells (MSCs). As expected, normal- and AML-stroma both protected 
tumor cells from spontaneous apoptosis, however ARQ531 efficacy was preserved, with no significant 
effect on the viability of MSCs (data not shown). Indeed, compared to spontaneous apoptosis of blast 
cells, ARQ531 increased cell death in AML cells cultured alone, and preserved its activity in the 
presence of normal or AML MSCs, suggesting that ARQ531 abrogates the survival benefit from 
stromal cells. (Fig.2A) Overall, our data indicate that ARQ531 is a potent anti-AML drug even in the 
presence of a tumor supportive microenvironment, and irrespective of FLT3 mutational status. (21)  
Finally, ARQ531 activity on normal cells was also investigated by employing clonogenic and viability 
assays in order to measure the impact of treatment on both CD34+ cells and mononuclear cells isolated 
from the bone marrow and peripheral blood of healthy donors. As shown in Figure 2 B-D, all of these 
cells were largely unaffected by ARQ531 exposure at dose levels toxic to tumor cells, proving that 
ARQ531 targets cancer cells without off-target effects on HSCs, resulting in a favorable therapeutic 
index.  
BTK signaling inhibition partially contributes to anti-AML activity of ARQ531 
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Based on its reported activity, we first studied the effect of ARQ531 on BTK-signaling by analyzing 
tumor cell migration. (27, 29-31). A transwell assay system was employed to investigate SDF-
1/CXCR4 axis in ARQ531 anti-AML activity. As shown in Supplementary Figure S3, ARQ531 
reduced tumor cell migration in response to stromal cell-derived factor 1 (SDF1) by 66% (P = 0.001), 
suggesting similar activity to ibrutinib (71% reduction; P <0.001).  
Next, to confirm the role of BTK in ARQ531 anti-AML activity, we investigated its effect on BTK-
signaling in AML cells over a range of concentrations. As shown in Figure 2E, ARQ531 treatment 
completely abrogated BTK activity as measured by Y223 phosphorylation, similar to the effects seen 
with ibrutinib treatment. However, as seen in Figure 1B, ARQ531 has anti-AML activity even on 
BTK-low expressing cells, suggesting that BTK targeting might not be critical for ARQ531 activity. To 
corroborate this hypothesis, we treated BTK-silenced (BTK knocked down, BTK-KD) AML cells with 
increasing doses of ARQ531. ARQ531 treatment reduced viability of both BTK-KD and BTK wild-
type cells to about 50% of control, demonstrating the importance of alternative targets for ARQ531 
activity in AML. (Fig.2F) 
ARQ531 treatment suppresses transcriptional oncogenic activity in AML cells 
To identify ARQ531-induced global perturbations in transcriptional profiling, we generated RNA-Seq 
data and performed functional annotation analysis of drug- versus DMSO-treated AML cells. As shown 
in Supplementary Figure S4A, principal component analysis (PCA) segregated samples based on 
treatment suggest a coherent transcriptional result rather than global, non-specific transcriptional 
silencing in response to this drug. Indeed, differential expression analysis identified 377 and 852 genes 
that were significantly up-regulated and down-regulated, respectively, with a ratio greater than 2-fold 
and P value <0.05. (Fig.3A, B) As a measure of the specificity of this effect, GSEA analysis was 
performed on the entire set of signatures available from the Molecular Signatures Database (MSigDB). 
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Biological modules associated with oncogenic transcriptional programs (e.g., ribosomal biogenesis and 
assembly, UPR stress and MYC) were significantly enriched in ARQ531-suppressed genes. (Fig.3C 
and Suppl. Fig.S4B) In line with these findings, although treatment did not exert significant 
suppression of gene sets for factors linked to pathophysiology of AML, such as C/EBPα-β, RUNX1, 
PU.1, ERG and FLI1, a significant reverse correlation was observed for transcriptional signatures of 
MYC-upregulated target genes, which in turn reflects the selective suppression of its transcriptional 
networks. (Fig.3D) Indeed, RT-PCR analysis of MYC and its target, CDC2, showed consistent 
downregulation following short-term exposure to the drug, (Suppl. Fig. S4C) pointing to ARQ531 as a 
selective suppressor of the MYC-regulated transcriptional pathway. To further support these data, we 
used ARQ531-expression signature to query the Library of Integrated Network-Based Cellular 
Signatures (LINCS) Program (www.lincscloud.org, web interface available at 
http://amp.pharm.mssm.edu/L1000CDS2/#/index). As shown in Figure 3E, the most significant 
ARQ531-correlated signatures were represented by those of oncogenic transcription factor inhibitors 
(such as fluvastatin, gefitinib and HDAC inhibitors) as well as those related to knockdown of ribosome 
subunits and translation initiation factors. Together, these data indicate that ARQ531 inhibits oncogenic 
transcriptional pathways in AML cells. 
ARQ531 interferes with the pro-survival MAPK pathway in OCI-AML3 cells  
As already reported, ARQ531 is a potent, ATP-competitive, reversible inhibitor of BTK and several 
additional kinases important to the viability, proliferation, activation, and motility of tumor cells. (27) 
Among the most intriguing additional targets of ARQ531 are RAF1 and MEK1, constituents of the 
ERK signaling pathway that is frequently dysregulated in tumor cells. (32-34) To confirm this activity 
in AML, cells were treated with increasing doses of ARQ531. As expected, activation of AKT and 
ERK was inhibited in a dose-dependent manner, likely due to predicted inhibition of RAF1 and MEK1. 
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(Fig. 4A) Subsequent experiments confirmed this hypothesis by revealing specific impairment of these 
kinases after ARQ531 treatment. (Fig. 4B) To support the pivotal role played by ERK, we exposed 
cells to the mitogenic effects of higher serum concentration (20%). As shown in Supplementary 
Figure S5 A-B, this strategy resulted in enhanced phosphorylation of ERK, which rescued the anti-
AML activity of this drug, thus providing evidence of ERK relevance in the observed anti-tumor effect. 
Moreover, consistent with RNA-Seq analysis, drug exposure resulted in prominent and specific 
downregulation of the oncogenic transcription factor MYC at the protein level. (Fig. 4B) Since the 
MAPK pathway enhances MYC protein stability by inducing its phosphorylation at serine 62, (35) we 
assessed p-MYC S62 changes in AML-treated cells. As shown in Figure 4C, ARQ531 exposure 
resulted in a prompt decrease of phosphorylation, followed by reduction of MYC protein. Accordingly, 
numerous MYC-addicted oncogenic cellular pathways, such as protein folding machinery, metabolic 
dependency and genome integrity, were compromised following this treatment, as highlighted by 
phospho-eukaryotic translation initiation factor 4E (eIF4e), ASCT2 and GLUT1 downregulation and 
γH2AX enhancement, respectively. (Fig. 4D) Combined drug screening revealed synergistic activity of 
ARQ531 with compounds affecting these programs, such as DNA damaging agents. (Suppl. Fig. S6 
A-B) Overall, these data support the existence of a mechanism of action that begins with MAPK 
signaling dysregulation and results in ARQ531-induced cytotoxicity in AML cells. Among MYC-
controlled programs, protein synthesis is emerging as the limiting step for tumor cell growth, (36) so 
we focused on this pathway. As shown in Figure 4D, AML cells treated with ARQ531 showed marked 
increases of eukaryotic translation initiation factor 4E-binding protein (4EBP1) with concomitant de-
phosphorylation of p70 ribosomal S6 kinase (p70-S6K) and eIF4e which result in blocking of mRNA 
recruitment to ribosomes for protein translation. (37) These data suggest that ARQ531 is a modulator 
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of several hubs controlling translation initiation in AML cells, providing evidence of marked protein 
synthesis inhibition specifically triggered by this treatment.  
Although MYC activation resulting from multiple tumor-driven genetic aberrations has been recognized 
as a major factor of leukemogenesis, its targeting did not show significant clinical benefit in AML. 
Thus, by using small interference RNA strategy (siRNA), we investigated the role of MYC in anti-
AML activity of ARQ531. As shown in Figure 4E, MYC-silenced HL-60 cells (MYC knocked down, 
KD) were treated with increasing doses of ARQ531. Surprisingly, despite their sensitivity to this 
treatment, cells were quite resistant to the loss of MYC protein expression, indicating that additional 
targets are implicated in anti-AML activity of this small molecule. 
Modulation of transcriptional regulatory machinery is an innovative strategy to treat AML. (38, 39) 
The oncogenic driver MYB, which is essential in hematopoiesis, is now emerging as a new target for 
anti-AML therapies. (40-45) We hypothesized that ARQ531 treatment of AML cells may inhibit this 
pathway. To validate this hypothesis, we measured MYB protein levels in ARQ531-treated cells. 
ARQ531 exposure resulted in marked MYB deregulation, (Fig. 4F) suggesting an important 
contribution to ARQ531 anti-tumor activity. To gain further insights into MYB reduction triggered by 
ARQ531, we tested proteasome contribution, as previously reported for other MYB-targeting agents.  
(43) As shown in Figure 4G, co-treatment with the proteasome inhibitor MG132 preserved MYB 
protein levels, suggesting that, in addition to its supposed effects on protein synthesis, ARQ531 affects 
MYB degradation. Therefore, our findings suggest that ARQ531 interferes with many pro-survival 
pathways, such as MAPK, in AML cells. 
ARQ531 dysregulates multiple oncogenic transcription factors in AML cells 
To gain insights into the molecular mechanisms of ARQ531, we analyzed treated HL-60 cells over 
time. As shown in Figure 5A, BTK signaling deregulation occurred early, after 2 hours of treatment, 
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followed by MYC downregulation. Importantly, apoptotic cell features, including PARP and caspase 3 
cleavage, were seen after MYB decrease, suggesting these events are crucial for ARQ531 anti-tumor 
activity. Published data show that small molecule BET inhibitors, by downregulating hematopoietic 
transcription factors, lead to potent therapeutic effects in several cancer models, including AML. (46, 
47) Therefore, we tested the anti-AML activity of the BTK inhibitor ibrutinib combined with the BET 
bromodomain inhibitor JQ1. (48) As was seen in other cell types, (25) the BET inhibitor enhanced the 
anti-tumor activity of the BTK inhibitor. (Fig. 5B) Western blot analysis of AML-treated cells 
confirmed these findings, further supporting the pivotal role of transcription factor deregulation in 
ARQ531 anti-AML activity. (Fig. 5C) Based on these data, we investigated the role of MYB in 
ARQ531 anti-AML activity by challenging BTK-silenced cells with the repurposed drug mebendazole, 
recently described as drug that induces MYB degradation. (44) As expected, mebendazole reduced cell 
viability of BTK-depleted cells more than control. (Suppl. Fig. S7A) We then performed several 
genetic studies to confirm these findings. As shown in Figure 6A, reduced viability was observed in 
MYC/MYB depleted cells compared with control, but more importantly, viability was significantly 
dampened in triple MYB/MYC/BTK silenced cells (reduction by 64.7% to 38.5%), suggesting that 
such inhibition is detrimental to AML cells. Consistently, simultaneous silencing of MYC, MYB and 
BTK resulted in PARP cleavage together with impairment of ERK phosphorylation. (Fig. 6B) Similar 
data were observed in BTK-KD cells. (Fig. 6C and Suppl. Fig. S7B) Nonetheless, the effect of triple 
knockdown was not quite equal to that of ARQ531 treatment, suggesting that other covalent or 
noncovalent targets are involved in its mechanism of action. 
Since MYB is reported to be crucial for leukemogenesis, (42, 49) we assessed the relationship between 
BTK and MYB in AML cells. Molecular data analysis of different publicly available AML cohort 
databases revealed higher expression of BTK and MYB in AML cells compared to normal HSCs, with 
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a positive correlation. (Suppl. Fig. S8 A-C) These data support the notion that several oncogenic 
pathways, including BTK, MYB and MYC, are essential for leukemia cells maintenance, supporting 
ARQ531 as an effective multi-targeted agent for the treatment of AML.     
ARQ531 shows potent activity in a patient derived (PDX) AML mouse model  
Based on in-vitro data, we next assessed whether ARQ531 treatment would be effective and tolerable 
in animal models by using our established AML patient-derived xenograft (PDX) model. NSG mice 
(n=20) were engrafted with 300.000 primary human AML cells (M4, acute myelomonocytic leukemia). 
Successful engraftment was documented by measuring circulating human CD45+ cells in mice 
peripheral blood with flow cytometry weekly for 2 months.  At day 19 post-graft, once a systemic 
xenograft was confirmed, mice were dosed orally with vehicle or ARQ531 (25 or 37.5 mg/kg; 5 
mice/each group) daily for 2 weeks. Percentage of human cells in peripheral blood samples was 
measured once a week up to day 42. (Fig. 7A) ARQ531-treated mice had significant reduction in 
hCD45+ cell numbers despite very rapid growth of the aggressive leukemic cells. (Fig. 7B) At day 42 
from treatment start, there were 66.5±0.1% and 69.5±0.2 % hCD45+ cells after ARQ531-treatment at 
37.5 and 25 mg/kg, respectively; in contrast, vehicle-treated mice had 85% hCD45+ cells (** 0.005< P 
<0.008; Fig. 7C). Also bone marrow and spleen analyses showed tumor burden (hCD45+) reduction, 
although it was not statistically significant. (Suppl. Fig. S9) In addition, ARQ531 treatment was found 
to significantly improve mouse survival. As shown in Figure 7D, Kaplan-Meier analyses indicated that 
ARQ531-treated mice, at higher dose, survived significantly longer than those treated with vehicle-
control (p<0.001). Overall, treatment was well tolerated as suggested by the maintenance of body 
weight and the lack of signs of toxicity, such as lethargy, ruffled fur, respiratory distress and hunchback 
posture (data not shown). Together these data indicate that in vivo ARQ531 administration was well 
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tolerated and efficiently reduced leukemia cell growth, providing impetus for clinical evaluation of this 
novel small molecule. 
DISCUSSION 
AML cells often demonstrate constitutive activation of tyrosine kinase signaling resulting from specific 
genomic aberrations. (16) These aberrations are attractive therapeutic targets, as demonstrated by the 
pharmacologic inhibitor of BTK, ibrutinib, which blocks AML blast proliferation, migration, and 
leukemic cell adhesion to bone marrow stromal cells. (15) However, BTK-based treatment of AML 
patients has been unsuccessful to date, (22) with only a few pre-clinical, ex-vivo reports suggesting that 
ibrutinib is effective against FLT3(ITD) and CD117 harboring cells, unlike the clinical benefit seen in 
patients with CLL and lymphoma. (18, 21) Adding inhibitory pressure on the BTK pathway might 
enhance the efficacy of this strategy, as previously reported. (19, 20, 50-54) In this study, using a 
combination of genetic and biochemical approaches, we extensively characterize ARQ531, a novel, 
reversible, orally bioavailable, ATP-competitive inhibitor of BTK and associated kinases. ARQ531 
greatly compromises AML cell survival by modulating transcriptional regulatory machinery 
coordinated by MYC, demonstrating activity both in-vitro and in a patient-derived xenograft (PDX) 
AML mouse model.  Thus, our study provides rationale for developing clinical trials using ARQ531 as 
a new treatment for patients with AML. 
Since ibrutinib does not directly inhibit members of the MAPK pathway, it is possible that the superior 
activity of ARQ531 in AML may be due to its modulation of additional targets, including kinases 
related to ERK signaling. (27) Although screening analysis of Src-family kinases (including Lyn and 
Syk) did not show any effect on AML cells, (55-57) (Suppl. Fig.S10) we assume that targeting of 
additional kinases is responsible for the high anti-AML activity of ARQ531. By combining 
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computational models and whole transcriptional analysis, we observed that ARQ531 treatment induces 
dysregulation of several transcription-addicted programs, including MYC and MYB. The combination 
of BTK inhibition and MYC/MYB downregulation explains the improved anti-AML activity of 
ARQ531 compared to single agent TKI’s such as ibrutinib. Since ARQ531 simultaneously inhibits 
different cellular functions such as folding machinery, metabolic dependency, and genome integrity, it 
may provide deeper and more durable remissions, while delaying the emergence of resistance. 
Additionally, based on reports that degrading MYB eradicates AML cells in mice without impairing 
normal myelopoiesis, (46) ARQ531 treatment may be safe for hematopoietic precursors cells, 
supporting its clinical relevance. We also provide experimental evidence that the bone marrow stroma 
is not affected by treatment and, more importantly, does not affect ARQ531 anti-tumor activity.  
Preliminary phase 1 studies confirm the ARQ531 safety profile, adding to the data that support its 
clinical development.  
Recent studies suggest that modulating transcriptional regulatory machinery is an innovative strategy to 
treat blood malignancies, including AML. (14, 38) An example of this strategy is all-trans retinoic acid 
(ATRA) treatment which, by modulating the transcriptional target PML-RARα, induces differentiation 
of leukemic blasts resulting in improved patients survival. (58) However, most transcription factors 
remain notoriously difficult to target, with siRNA-mediated silencing of gene expression being one of 
the few feasible approaches. (59) Other oncoproteins, including MYC and MYB, are emerging as 
compelling targets for drug development in AML, due to their ability to influence tumor proliferation. 
(40-44, 60, 61) In this context, the new small molecule ARQ531, by affecting multiple oncogenic 
pathways simultaneously, results in perturbation of the transcriptional regulatory machinery which 
maintains AML cell integrity. Therefore, targeting BTK, MYC and MYB with ARQ531 represents an 
innovative strategy for improving the efficacy of AML therapy.  
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In summary, we have demonstrated that ARQ531, a new reversible tyrosine kinases inhibitor, 
suppresses AML cells viability in vitro and in vivo by abrogating different oncogenic targets including 
BTK, MYC and MYB. Gene silencing of BTK, MYC and MYB in AML cells was not as effective as 
ARQ531, suggesting that other covalent or noncovalent targets are involved in its mechanism of action. 
Based on our preclinical data, we provide the rationale to explore the effects of this multi-targeted 
agent on hematologic malignancies as well as solid tumors, beyond investigating its clinical benefit in 
AML patients. 
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TABLES 
Table 1. AML patient characteristics 
 
 
Patient FAB classification karyotype NPM FLT3-ITD ELN RISKGROUP 
AML-013 AML M2 normal MUT wt low 
 AML-012 AML M1 normal MUT MUT int. 
 AML-011 AML M6 complex wt wt high 
AML-009 AML M2 50XX wt wt high 
AML-007 AML M3 t(15;17) / wt  M3 
AML-006 AML  M4 normal MUT MUT  low 
AML-005 AML M2 normal MUT MUT  low 
AML-004 AML M4 normal MUT wt low 
  AML-003 AML M2 normal wt wt int 
 AML-001 AML M3 t(15;17) / MUT  M3 
 AML-008 AML M3 t(15;17) / wt M3 
 AML-010 AML M4 n.a wt wt int. 
 AML-002 AML M2 normal MUT wt high 
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FIGURE LEGENDS 
Figure 1. ARQ531 shows strong anti-tumor activity by inducing AML cells apoptosis. A) 
Immunoblot for phospho-BTK, BTK and GAPDH (loading control) in the indicated human AML cell 
lines and primary AML samples regardless of specific genomic landscape. B, C) Viability of AML cell 
lines after ARQ531 (B) or ibrutinib (C) treatment as measured by MTS assay. Displayed are the mean 
± standard deviation (SD) from at least 3 independent experiments. D) IC50 values measured for each 
tested cell line as B and C. E) Drug effects on primary AML patient-derived samples (n=13) treated 
with increasing doses of ARQ531 or ibrutinib (0-30µM for 48 hours). IC50 values are visualized for 
each tested primary AML cell lines F) HL60, OCI-AML2 and primary AML-002 cells were treated 
with ARQ531 or DMSO (CTR) in a dose-dependent manner for 48 hours. Apoptotic cells were 
detected by Annexin V/PI staining. Representative dot plots are shown. G) Immunoblots for PARP, 
caspase 3, MCL-1, BCL-2 and tubulin on indicated AML cell lines and primary blast cells following 
BTK inhibitor treatment (ARQ531 vs ibrutinib) at 24 hours. 
Figure 2. ARQ531 triggers anti-AML toxicity regardless of BTK activity and presence of stromal 
cells but preserves normal HSCs. A) Viability of OCI-AML2 GFP/luc+ cells treated with ARQ531 
for 48 hours, alone and in presence of normal MSCs (blank) or AML-MSCs (grey) stroma, measured 
by luciferase-based luminescence assay. Data are represented as mean +/− SD in all histograms (n = 3). 
*0.02<p<0.03; **p < 0.05. B-D) Healthy donor (HD) derived hematopoietic precursor (BM-CD34+) 
and PBMCs were exposed to increased doses of ARQ531, and clonogenic abilities (C) or viability (B, 
D) were calculated. Colony formation of ARQ531-treated cells (CFC) were measured after 2 weeks. 
Viability was calculated as propidium iodide-negative cells among CD34+ population. Data are 
represented as mean +/− SD (n = 3); unpaired t test, ***p < 0.001, ****p < 0.0001. E) Western blot 
showing that ARQ531 treatment effectively abrogates BTK signaling cascade in three different human 
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AML cell lines (HL60, OCI-AML3 and MOLM14) following 24 hours of treatment. Ibrutinib effect is 
also shown as a positive control. F) Viability of BTK-silenced (nucleofected with specific siRNAs 
targeting BTK) or control HL60 cells (siRNA scramble) treated with increasing doses of ARQ531 for 
48 hours. Displayed are data represented as mean +/− SD in all (n = 3). 
Figure 3. Molecular perturbation triggered by ARQ531 in AML cells. A) Heatmap for the highest 
50 down- and up-regulated genes (p< 0.0001) following ARQ531 treatment of OCI-AML 3 cells. B) 
Volcano plot of RNA-seq of drug- versus DMSO-treated cells in OCI-AML3 showing that 377 and 852 
genes were significantly up- and down-regulated, respectively, with a fold change (FC) > 2. C) Table 
of the ten most significantly enriched gene sets, from the Hallmark collection, enriched with genes 
downregulated by ARQ531 in AML cells. Number of genes in each set (n), the normalized enrichment 
score (NES), and test of statistical significance false discovery rate (FDR) q value are highlighted. D) 
Enrichment plots of top-four most significantly enriched gene sets (MYC-related) in transcriptional 
profiles of AML cells treated (right) or untreated (left) with ARQ531. E) Connectivity score generated 
by LINCS L1000 Characteristic Direction Signature Search Engine tool, that compared ARQ531-
derived transcriptional profile against 10,000 “perturbagen” signatures (corresponding to short-hairpin 
RNA, open reading frame and compounds). Top-ranked scores of relevant results are indicated by 
arrow. 
Figure 4. BTK inhibition and MYC/MYB degradation represent molecular basis for ARQ531 
anti-AML activity. A) Western blot showing that 24h of ARQ531 (0.3-1 μM) treatment abrogates 
ERK and AKT activation in HL60 and OCI-AML2 cells. B) Western blot analysis shows that 24h of 
ARQ531 treatments (0.3-1 μM) affects kinases in the RAF/MEK/ERK pathway of AML cell lines, 
resulting in MYC-downregulation. C) Western blot showing time-dependent effects of ARQ531 
exposure to p-MYC S62 and total MYC in HL60 cell line. D) Western blot showing deregulation of c-
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MYC controlled signals in AML cells following treatment with ARQ531 at indicated doses following 
24h. E) Viability of MYC-silenced or control HL60 cells treated with increasing doses of ARQ531 for 
48 hours. Displayed are data represented as mean +/− SD in all (n = 3). F) Protein and mRNA 
expression in AML cells after 24 h treatment with DMSO or indicated ARQ531 concentrations, 
normalized to DMSO controls. Bars and error bars are means and SD of three independent 
experiments. *P<0.05; **P=0.01; ***P<0.001; n.s. not significant (relative to DMSO controls), one 
sample t-test. Western blots below graphs show examples of MYB protein expression. G) Western blot 
analysis of MYB protein expression in AML cells after 24 h treatment with DMSO, ARQ531 (0.3-1 
μM) or ARQ531 and 10 μM MG132, a proteasome inhibitor.  
Figure 5. ARQ531 treatment results in oncogenic program dysregulation in AML cells. A) 
Western blot analysis of ARQ531 (1 μM) treated cells after indicated hours. Time-dependent effects 
demonstrate early inhibition of BTK activity and MYC downregulation followed by MYB reduction 
with associated PARP and caspase 3 cleavage. B) Treatment of HL60 cells with BET bromodomain 
inhibitor JQ1 (400nM), ibrutinib (30 µM) or their combination which resulted in synergistic effect. 
Bars and error bars are means and SD of three independent experiments. ***P<0.001 (relative to 
DMSO controls), one sample t-test. C) Western blot showing that ibrutinib, JQ1, or the combination 
result in appearance of apoptotic features, including caspase 3 and PARP cleavage in HL60 cells  
Figure 6. ARQ531 affects BTK, MYC and MYB in AML cells. A) BTK, MYC, MYB, and 
especially their simultaneous silencing considerably reduced viability of HL60 cells as measured by 
Typan blue staining. Displayed are the mean of triplicates. B) and C) Triple BTK/MYC/MYB silenced 
HL60 cells demonstrate diminished phosphorylation of ERK and PARP full length form compared 
with cells depleted either transiently (B) or stably (C) of each gene, individually. 
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Figure 7. ARQ531 inhibits tumor growth and extends survival in patient-derived xenograft 
(PDX) AML mouse model. A) Experimental outline for the analysis of the anti-leukemic activity of 
ARQ531 against primary human AML cells. Patient-derived xenograft mouse model of human primary 
AML cells was used to assess the efficacy of ARQ531 against AML cells isolated from patients with 
AML M4. B) Representative flow cytometric dot plots representing tumor engraftment evaluated at day 
35 after treatment. On the right panel, histogram represents percentage of human CD45+ cells in mice. 
Data are represented as mean ± SD; **P=0.006; **** P<0.001. C) Circulating human CD45+ cells 
were measured in peripheral blood by flow cytometry weekly for 2 months. At day 19, a systemic 
xenograft was confirmed (tumor engraftment) and mice were randomized to receive vehicle control, 
ARQ531 low dose (25 mg/kg) or high dose (37.5 mg/kg). Percentage of human leukemic cells in 
peripheral blood of mice was measured weekly, up to day 42. ** 0.005< P <0.008. D) Kaplan-Meier 
curve of PDX AML-model following treatment with vehicle, ARQ531 at low dose (25 mg/kg) or high 
dose (37.5 mg/kg). Higher drug-schedule led to significant longer overall survival compared with 
vehicle-control treated mice (5 mice/group; p<0.001). 
 
 
 
  







SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Cell lines  
The AML cell lines ML2, MOLM-14, MV4-11, HL60, NOMO-1, OCI-AML2, OCI-AML3 and NB4 
were provided by collaborators or purchased from ATCC or DSMZ (Braunschweig, Germany). All cell 
lines were cultured in RPMI-1640 medium containing 10% FBS (GIBCO, Life Technologies, Carlsbad, 
CA), 2 μM l−1 glutamine, 100 U ml−1 penicillin, and 100 μg ml−1 streptomycin (GIBCO, Life 
Technologies, Carlsbad, CA). 293T cell line was purchased from ATCC and cultured in DMEM 
containing 10% FBS (GIBCO, Life Technologies, Carlsbad, CA), 4mM glutamine, 50 U ml/m1 
penicillin, and 50 U/ml streptomycin (GIBCO, Life Technologies, Carlsbad, CA). 
Primary cells 
All studies involving human samples were performed under Policlinico San Martino Hospital (Genoa, 
Italy) IRB committee-approved protocols, after informed consent; de-identified samples were utilized.  
Primary leukemic cells were obtained from peripheral or bone marrow blood of 13 AML patients at 
diagnosis, before treatment. (Table 1) (1) The percentage of leukemic blasts was always > 90%. Normal 
CD34+ cells (HSCs) were isolated from the bone marrow (BM) of healthy donors using anti-CD34 
magnetic-activated microbeads and MiniMacs high-gradient magnetic separation column (Miltenyi 
Biotec, Bergisch Gladbach, Germany). This strategy generated highly purified CD34+ cells (> 90%, as 
confirmed by FACS staining). Cells were either used immediately for viability assays or for mRNA 
isolation, or stored at −80°C in medium containing 50% FBS and 10% DMSO. Normal or AML MSCs, 
isolated as previously described, (2) were seeded in 96 well plates 1 × 104/well, AML cells were added 
to the confluent layer at 10:1 ratio. After overnight incubation, cells were used as indicated.  Normal 
mononuclear cells (MNCs), obtained from the BM of healthy donors were isolated by Ficoll-Hypaque 
centrifugation (Amersham Bioscience, Piscataway, NJ, USA).  
Cell Viability and Apoptosis Assay  
Cell viability was assessed by using CellTiter 96 AQueous One Solution Cell Proliferation Assay 
(Promega Corporation, Madison, WI, USA), as previously described. (3)  Apoptosis was evaluated by 
flow cytometric analysis following Annexin V–FITC (BD Biosciences, 556419) and PI (BD Biosciences, 
51-6621E) staining, according to manufacturer’s instructions. The percentage of cells undergoing 
apoptosis was defined as the sum of early apoptotic (annexin V+PI−) and late apoptotic (annexin V+PI+) 
cells. 
RNA Seq processing, differentially expressed genes detection and gene set enrichment analysis 
OCI-AML3 cells were treated with 1 µM ARQ 531 or vehicle control for 12 hours. RNA was prepared 
as mentioned earlier. A starting amount of 500 ng of RNA was used to prepare polyadenylate-enriched, 
single bar–coded libraries using the NEBNext Kit. Quality control of the libraries was evaluated by 
Bioanalyzer analysis with High Sensitivity chips (Agilent Technologies). Sequencing was performed on 
a HiSeq 2500 (Illumina) by 2× 50–base pair paired-end reads at the Biopolymers Facility of Harvard 
Medical School. We used Bcbio-next gen (https://github.com/bcbio/bcbio.nextgen/) to process the RNA-
seq data. Briefly, cutadapt (https:// github.com/marcelm/cutadapt/) was used to trim adapters; trimmed 
reads were aligned to human reference genome (GRCh37) by tophat2; and read counts for each gene 
were calculated by HTSeq under standard parameters. Genes with low expression (fragments per 
kilobase million, FPKM, <1 across all samples) were filtered out. Degust (http://degust.erc.monash.edu/) 
was used for data visualization and differential analysis using edgeR. GSEA 
(https://software.broadinstitute.org/gsea/) was used on the pre-ranked gene lists, by applying 1000 
permutations and using a weighted statistic enrichment. Significant enriched gene sets (16) were selected 
with a threshold FDR<0.25. Gene sets were downloaded from the Broad Institute’s MSigDB 
(https://software.broadinstitute.org/gsea/msigdb/). 
 
Western blotting  
Whole-cell lysates were prepared as previously described. (3) Protein concentrations were determined 
by Bradford assay (Bio-Rad, CA), and equivalent amounts (40μg) were subjected to SDS-PAGE, 
transferred to PVDF membranes immunoblotted with following antibodies: anti-GAPDH (#5174, Cell 
Signaling Technology), -phospho-Histone H2A.X (Ser139) (#05-636, Millipore), -RAD51 (#588-B01P, 
Novus Biologicals), -Phospho-Btk (Tyr223) (#5082, Cell Signaling Technology), -BTK (#8547, Cell 
Signaling Technology), -γ tubulin (#MA1-850, ThermoFischer Scientific), -PARP (#9532, Cell 
Signaling Technology), -Caspase3 (#9662, Cell Signaling Technology), -Bcl2 (#sc-509, Santa Cruz 
Biotechnology), -Mcl1 (#sc-819, Santa Cruz Biotechnology), -Phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) (#4370, Cell Signaling Technology), -ERK1/2 (#9102, Cell Signaling Technology), 
Phospho-Akt (Ser473) (#4058, Cell Signaling Technology), AKT (#9272, Cell Signaling Technology), 
phospho-c-Raf (Ser338) (#9427, Cell Signaling Technology), phospho-MEK1/2 (Ser217/221) (#9154, 
Cell Signaling Technology), c-MYC (#9402, Cell Signaling Technology), Cyclin D1 (#2978, Cell 
Signaling Technology), Cyclin D3 (#2936, Cell Signaling Technology), Phospho-eIF4E (Ser209) 
(#9741, Cell Signaling Technology), Non-phospho-4E-BP1 (Thr46) (#4923, Cell Signaling 
Technology), Phospho-eIF2α (Ser51) (#3398, Cell Signaling Technology), Phospho-p70 S6 Kinase 
(Thr389) (#9206, Cell Signaling Technology), ASCT2 (#8057, Cell Signaling Technology), GLUT1 
(#12939, Cell Signaling Technology), RAD51 (#sc-8349, Santa Cruz Biotechnology), c-MYB (clone 1-
1) (#05-175, Millipore). Band intensities were quantified by Quantity One SW software (Bio-Rad 
Laboratories, Inc) using standard ECL Western Blotting Detection Reagents (Thermo Fisher Scientific, 
IL). Densitometric analysis of western blots was carried out using ImageJ software version 1.48 (National 
Institute of Health). 
 
 
Lentiviral mediated gene transfer  
pLV sh SCRAMBLE and pLV shBTK  lentiviral vectors were purchased from Vector Builder (Vector 
Builder Inc., Santa Clara, USA) . For lentiviral transduction, 1× 106 293T cells were plated on 60 mm 
Petri dishes and allowed to adhere for 24 h. Thereafter, cells were transfected with 1μg of lentiviral 
plasmidic DNA and 700ng of each of three packaging vectors (pRP CMV VSVG; pRP CMV gag:pol 
RRE; pRP CMV RSV Rev), using TransIT-293 (Mirus Bio, Madison, WI) according to the 
manufacturer's instructions. 48 and 72h after transfection, the supernatant containing lentiviral particles 
was harvested, filtered with a 0.45-μm-diameter filter, and used to infect 1.5× 106 AML cells. AML cells 
were spinoculated at 750g for 45 min in presence of 8 μg ml−1 polybrene, (Santa Cruz Biotechnologies, 
CA), incubated with viral supernatant for 6 h and left overnight in normal culturing medium. The day 
after, a second cycle of infection was performed. Successfully infected cells were selected using a 
suitable concentration of puromycin (1 μg ml−1). 48 and 72 h after selection, the transduction efficiency 
was approximated by counting the proportion of cells expressing the fluorescent protein (GFP) using a 
fluorescence microscope (Nikon Eclipse 80i, Nikon, Melville, NY); and the knockdown efficiency was 
validated by protein level with WB analysis. Functional studies were performed as described below. 
RNA Extraction and RT PCR.  
Total RNA was extracted from cells using RNeasy Plus mini kit (Qiagen S.r.l., Milan, Italy) according 
to the manufacturer's instructions. 1 μg RNA was reverse transcribed in a final volume of 100 μl using 
High Capacity cDNA Reverse Transcription kit (Life Technologies, Monza, Italy). 5 μl of the resulting 
cDNA were used for qPCR with a QuantStudio5 Real-Time PCR (Applied Biosystems by Life 
Technologies, Monza, Italy). Primer sequences were as follows: MYB Fw 5’-                                                                                                                                                           
CAAGCTCCGTTTTAATGGCAC-3’, Rev 5’-ATCTTTCCACAGGATGCAGG -3’  ; GAPDH     Fw 
5’-TCTCCTCTGACTTCAACAGCGAC-3’, Rev 5’-CCCTGTTGCTGTAGCCAAATTC-3’. mRNA 
levels were detected using SYBR Select Master Mix (Applied Biosystems, Italy) according to the 
manufacturer's protocol. Gene expression was normalized to housekeeping gene expression (GAPDH). 
Comparisons in gene expression were calculated using the 2−ΔΔCt method. 
Colony forming unit (CFU) assay 
Immediately after their purification, CD34+ HSCs were plated in HSC004 methylcellulose medium 
(R&D) supplemented with EPO 3 IU/ml and IL-6 20ng/ml at a concentration of 1x103 cells per plate and 
treated (in duplicate) with different concentrations of ARQ531 or DMSO as control.  All plates were 
incubated at 37°C, 5% CO2 for 10-14 days before counting the number of colonies.  
BMSC conditioned media 
10 x 105 Healthy donor- or Patient derived-BMSC were plated in 6 well plates and left to adhere for 24 
hours. The day after, medium was replaced with 2 ml of complete RPMI-1640 and cells were cultured 
for 5 days. Thereafter, BMSC-conditioned media were collected, filtered with 0,45 µM filters and 
immediately used for AML cells resuspension. Finally, drugs or vehicle were added at 20X 
concentration, in order to not dilute conditioned media. After 48 hours cell viability was measured as 
indicated.  
Tumor cell-specific bioluminescence imaging in co-cultures with stromal cells 
7x103 Luciferase+ AML cells (OCI-AML2 Plv sv40 GFP/luc+) were plated in 96-well optical white 
plates (Corning, Cat.No.3903) in the presence or absence of pre-plated luciferase−  primary stromal cells 
(20 x103 cells seeded 24hours before) and treated with drugs or veichle (DMSO), as indicated in each 
experiment. After 48 h of treatment, AML cell specific viability was assessed with Nano-Glo® Live Cell 
Assay System (Promega, Cat.No. N2011) 
Nucleofection 
HL60 cells were transfected by using the 4D-Nucleofector™ System (Lonza), according to 
manufacturer’s instruction. Small interfering RNAs (siRNAs) targeting human BTK (ON-TARGET plus 
SMART pool, #L-003107-00-0005) and a non-targeting negative control (ON-TARGET plus non-
targeting pool #D-001810-10-05) were purchased from Dharmacon. siRNAs targeting human Myc or 
Myb were purchased from ThermoFisher Scientific (Myc siRNA#1 Dharmacon J-003282-23; Myb 
ThermoFisher Scientific #AM16708, pool of siRNA ID 115653 and 10768); #AM16708, pool of siRNA 
ID 115653 and 107687). For each nucleofection, 2 x 106 cells was pulsed with the EN-138 program, 
using Amaxa SF Cell line 4-D Nucleofector X KitL (Cat.No. V4XC-2024, Lonza). In this procedure, all 
siRNAs were used at the final concentrations of 500 nM. After 24h from nucleofection, cells were 
cultured and then treated or collected for further experiments. 
Immunofluorescence and focal microscopy 
Cells were prepared as previously described, (3) using specific primary and secondary antibodies. The 
slides were then mounted with ProLong Gold Antifade reagent (Invitrogen, Life Technologies, Carlsbad, 
CA), and images were taken using a Leica TCS SP confocal laser scanning microscope (Leica 
Microsystems, Wetzlar, Germany), equipped with 476, 488, 543 and 633 excitation lines with a 60 x 
Plan Apo oil objective. 
Human Data Sets.  
Expression levels of BTK were obtained from the TCGA cohort among their low or high expression of 
BTK. (BloodPortal data of BTK probe 205504_at from U133 Plus 2.0 array). 
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Supplementary Figure Legends. 
 
Supplementary Figure 1. BTK expression in AML cells. BTK mRNA expression in AML as 
compared to other cancers, on the basis of data from The Cancer Cell Line Encyclopedia (CCLE) 
database. Data are presented as mean log2 expression with range; in red are highlighted AML cell lines 
(n=39).  
Supplementary Figure 2. Anti-tumor activity of ARQ531 is dependent of caspase activation. A) 
HL60, OCI-AML2 and primary AML-004 cells were treated with increasing doses of ARQ 531 (1-10 
µM) or DMSO for 48 hours. Apoptotic cell death was measured by Annexin V/PI staining and flow 
cytometric analysis. The percentage of each group is shown as solid columns. Data are derived from 3 
independent experiments. B) HL60 cells were pretreated with caspase inhibitors (zVAD-fmk 50 µM), 
for 2 hours and then incubated with ARQ531 at indicated concentrations for 48 hours. Specific cell death 
was then measured with MTS assay. 
Supplementary Figure 3. ARQ531 and Ibrutinib inhibit AML cell migration in response to SDF-
1. HL60 cells were pretreated with ibrutinib (500nM) or ARQ531 (500nM) for 1 h before wash-off and 
then placed in the upper well of a 8.0µM transwell plate. The lower chamber contained 500ul of serum 
free media supplemented with SDF1 (100 ng/ml) for 3 hours and then assessed for cell number using 
trypan blue staining. Data were normalized to DMSO treated cells.*** p=.001; **** p<.0001 
Supplementary Figure 4. Molecular perturbation triggered by ARQ531 in OCI-AML3 cells. A) 
Principal component analysis (PCA) of control and ARQ531 treatment on OCI-AML3 cells. B) GSEA 
analysis was performed on the entire set of signatures available from the Molecular Signatures Database 
(MSigDB). C) mRNA levels of selected genes were analyzed by qPCR in OCI-AML3 cell lines treated 
with 0.3 and 1 µM of ARQ 531 or ibrutinib for 24 hours. The graph shows the fold change compared to 
untreated cells. 
Supplementary Figure 5. The pro-survival MAPK pathway has a crucial role for anti-AML activity 
of ARQ 531. A) HL60 cells were treated with increasing concentrations of ARQ531 w/w 20% FBS. 
After 24 hours, cells were collected for western blot analysis. In parallel viability was measured by MTS 
assay after 48 hours of drug exposure. B) HL60 cells treated with ARQ531 or Ibrutinib in presence or 
not of 20% FBS for 24h were subjected to blot analysis for phospho-ERK1/2, ERK1/2, c-Myc and tubulin 
as shown.  
Supplementary Figure 6. ARQ531 treatment enhances genomic instability of AML cells. A) 3 x 106 
HL60 cells were treated with ARQ531 for 24hours, using Doxorubicin as positive control. Thereafter, 
cells were washed with PBS, fixed and stained. γH2AX foci and nuclei (Q-nuclear) were visualized by 
confocal microscopy. B) 2 x 105 HL60 cells were plated in 96 well plate and treated for 48 hours with 
indicated doses of ARQ531 (0.3 µM) in presence or not of DNA damaging agents including idarubicin 
and Ara-C at indicated doses. Cell viability was than measured by MTS assay. Combination index was 
calculated by CalcuSyn software and reported above the columns indicating specific co-treatment. Data 
are represented as mean +/− SD in all histograms (n = 2). **0.01<p<0.05; ***p < 0.001. 
Supplementary Figure 7. ARQ531 targets BTK and Myb in AML cells. A) Treatment of BTK-KD 
HL60 cells with increased doses of Mebendazole (0.2-1.8 µM) resulted in higher anti-AML activity of 
this drug. B) BTK, MYC/MYB, and especially triple gene knockdown considerably reduced viability of 
HL60 cells as measured by Typan blue staining. Displayed are the mean of triplicates.  
Supplementary Figure 8. MYB and BTK expression highly correlate in AML patients. A) 
Microarray data from GSE13204 database are expressed as histogram plots (25th-75th percentiles) for 
BTK (A) and MYB (B) expression in AML patients (n = 542) and ND (n = 73). The data were log2 
transformed and median centered (dark lines). C) Microarray gene expression data from GSE13204 data 
sets was robust multiarray average normalized and the correlation between BTK and MYB expression 
in AML patients was assessed by the Spearman rank-order correlation, where P < .05 was considered as 
statistically significant. 
Supplementary Figure 9. ARQ531 inhibits tumor growth in AML patient-derived xenograft (PDX) 
mice model. Tumor engraftment was determined by flow cytometry in bone marrow (BM) and spleen at 
day 53. Evaluated markers: human CD45. Any significant difference was observed among groups. 
Supplementary Figure 10. ARQ531screening analysis on Src-family kinases. Immunoblots for CSK, 
FGR, HCK, YES, FYN, LCK pSRC and tubulin on OCI-AML3 cells following ARQ531 treatment at 24 
hours at indicated doses. 
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Figure S4
Myc-dependent Gene Set Size ES NES FDR q-val
SCHUHMACHER_MYC_TARGETS_UP 39 -0,59 -2,97<0.0001
HALLMARK_MYC_TARGETS_V1 87 -0,48 -3,01<0.0001
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MYC_UP.V1_UP 32 -0,62 -2,91<0.0001
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